Toxoplasma replication is inhibited by MMV676477 without development of resistance
Izra Abbaali1, Danny Truong1, Dawn M Wetzel2
1Department of Molecular Biology and Biochemistry, University of California, Irvine, California, USA.
Cytoskeleton (Hoboken, N.J.)
|May 17, 2024
Summary
A novel compound, MMV676477, effectively inhibits the growth of the parasite Toxoplasma gondii by targeting protozoan tubulin. This drug shows promise for treating parasitic infections with a low risk of resistance development.
Area of Science:
- Parasitology
- Molecular Biology
- Drug Discovery
Background:
- Protozoan parasites cause severe human and animal diseases.
- Current treatments are limited by toxicity and drug resistance.
- Protozoan tubulin is a promising target for broad-spectrum antimitotic agents.
Purpose of the Study:
- To evaluate the efficacy of MMV676477 against Toxoplasma gondii.
- To assess the safety and resistance potential of MMV676477.
Main Methods:
- In vitro anti-parasitic activity assay against T. gondii.
- Microtubule stabilization assay in vertebrate cells.
- Forward genetics screen for drug resistance.
Main Results:
- MMV676477 inhibited T. gondii growth with an EC50 of ~50 nM.
- The compound did not affect vertebrate microtubules or exhibit toxicity in human fibroblasts.
- No resistant T. gondii strains emerged, suggesting a low resistance potential.
Conclusions:
- MMV676477 is a potent inhibitor of T. gondii.
- The drug is selective for protozoan tubulin, with a low risk of resistance.
- MMV676477 represents a promising scaffold for developing new anti-parasitic therapies.
